Method for administering selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing the treatment
| Title: | Method for administering selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing the treatment |
|---|---|
| Patent Number: | 7,635,491 |
| Publication Date: | December 22, 2009 |
| Appl. No: | 11/019513 |
| Application Filed: | December 23, 2004 |
| Abstract: | The invention concerns the use of at least a molecule containing selenium, in an amount corresponding to a daily dose of about 2 to 40 mg, even 80 mg of atomic selenium equivalent, on its own or combined with other synergetic molecules for controlling oxidative stress and excessive inflammatory reaction: zinc, vitamin E, vitamin C, iron binder, glutathione precursor, copper and/or copper input binder, for preparing a medicine for treating severe systemic inflammatory response syndrome, in particular any acute infectious condition endangering the patient's life whether of bacterial, parasitic, fungal or viral origin, and any condition corresponding to a severe onset of inflammatory pathology bringing about an exacerbation of cytokine secretion. The invention is applicable in human and veterinary medicine. |
| Inventors: | Forceville, Xavier (77860 Saint Germain sur Morin, FR); Vitoux, Dominique (Paris, FR) |
| Assignees: | Forceville, Xavier (Saint Germain sur Morin, FR) |
| Claim: | 1. A method for treating an adult patient having severe systemic inflammatory response syndrome, comprising: administering to said patient an effective amount of a composition comprising at least one molecule containing selenium, wherein said effective amount is a daily dose of a selenium composition containing about 0.025 to 1 mg/kg of bodyweight of atomic selenium, and wherein said molecule containing selenium is a selenium-containing protein consisting of a selenoprotein. |
| Claim: | 2. The method of claim 1 , wherein the daily dose of atomic selenium ranges from 0.05 to 0.5 mg/kg of body weight. |
| Claim: | 3. The method of claim 1 , wherein the daily dose of atomic selenium ranges from 0.0375 to 0.75 mg/kg of body weight. |
| Claim: | 4. The method of claim 1 , wherein the selenoprotein is selected from the group consisting of selenoprotein Pa (SelPa), selenoprotein W (SelW), selenoprotein T (SelT), selenoprotein R (SelR or SelX), 15 kDa selenoprotein (Sep15), selenoprotein N (SelN), selenoprotein T2 (Sel T2), selenoprotein M (SelM), selenoprotein G-rich (G-rich), selenoprotein W2 (SelW2), selenoprotein BthD (BthD), selenoprotein H (SelH), selenoprotein I (SelI), selenoprotein K (SelK), selenoprotein O (SelO), selenoprotein P (SelP), selenoprotein R (SelR), selenoprotein S (SelS) and selenoprotein Pb (SelPb). |
| Claim: | 5. The method of claim 1 , wherein the selenoprotein is a human selenoprotein P selected from the group consisting of the 61 kDa selenoprotein P isoform and the 51 kDa selenoprotein P isoform. |
| Claim: | 6. The method according to claim 1 , wherein said patient is treated for a severe systemic inflammatory response selected from the group consisting of peritonitis, pneumonia, meningitis and bacterial septicemias in a septic shock state. |
| Claim: | 7. The method according to claim 1 , wherein said patient is treated for a severe systemic inflammatory response selected from the group consisting of bacterial infections, parasitic infections, fungal infections, viral infections and rheumatoid polyarthritis. |
| Claim: | 8. The method according to claim 1 , wherein said patient is treated by an exposure to ionizing radiation. |
| Claim: | 9. The method according to claim 1 , wherein more than one selenoprotein is administered. |
| Claim: | 10. The method according to claim 1 , wherein said selenoprotein-containing composition is administered by a parenteral route, intraperitoneal route or oral route. |
| Claim: | 11. The method according to claim 1 , wherein said composition further comprises a non-selenium compound which is selected from the group consisting of vitamin E, vitamin C, a glutathione precursor, an iron chelator, a copper chelator, copper, chromium, zinc and gold. |
| Claim: | 12. A method for treating an adult patient having severe systemic inflammatory response syndrome, comprising: administering in a first treatment to said patient an effective amount of at least one molecule containing selenium, wherein said effective amount is a daily dose of a selenium composition containing about 0.025 to 1 mg/kg of bodyweight of atomic selenium, followed by further administering to said patient a second treatment of an effective amount of at least one molecule containing selenium, wherein said effective amount in said second treatment is a daily dose of a selenium composition containing about 0.00625 to 0.025 mg/kg of atomic selenium, and wherein said molecule containing selenium is a selenium-containing protein consisting of a selenoprotein. |
| Claim: | 13. The method of claim 12 , wherein the daily dose of atomic selenium ranges from 0.05 to 0.5 mg/kg of body weight. |
| Claim: | 14. The method of claim 12 , wherein the daily dose of atomic selenium ranges from 0.0375 to 0.75 mg/kg of body weight. |
| Claim: | 15. The method of claim 12 , wherein the selenoprotein is selected from the group consisting of selenoprotein Pa (SelPa), selenoprotein W (SelW), selenoprotein T (SelT), selenoprotein R (SelR or SelX), 15 kDa selenoprotein (Sep15), selenoprotein N (SelN), selenoprotein T2 (Sel T2), selenoprotein M (SelM), selenoprotein G-rich (G-rich), selenoprotein W2 (SelW2), selenoprotein BthD (BthD), selenoprotein H (SelH), selenoprotein I (SelI), selenoprotein K (SelK), selenoprotein O (SelO), selenoprotein P (SelP), selenoprotein R (SelR), selenoprotein S (SelS) and selenoprotein Pb (SelPb). |
| Claim: | 16. The method of claim 12 , wherein the selenoprotein is a human selenoprotein P selected from the group consisting of the 61 kDa selenoprotein P isoform and the 51 kDa selenoprotein P isoform. |
| Claim: | 17. The method according to claim 12 , wherein said patient is treated for a severe systemic inflammatory response selected from the group consisting of peritonitis, pneumonia, meningitis and bacterial septicemias in a septic shock state. |
| Claim: | 18. The method according to claim 12 , wherein said patient is treated for a severe systemic inflammatory response selected from the group consisting of bacterial infections, parasitic infections, fungal infections, viral infections and rheumatoid polyarthritis. |
| Claim: | 19. The method according to claim 12 , wherein said patient is treated by an exposure to ionizing radiation. |
| Claim: | 20. The method according to claim 12 , wherein said first treatment is administered during a time period between a first day to fourth day of the method, and said subsequent treatment is administered 1 to 20 days after said first treatment. |
| Claim: | 21. The method according to claim 12 , wherein more than one molecule containing selenium are used. |
| Claim: | 22. The method according to claim 12 , wherein said selenium-containing composition is administered by a parenteral route, intraperitoneal route or oral route. |
| Claim: | 23. The method according to claim 12 , wherein said composition further comprises administering a non-selenium compound which is selected from the group consisting of vitamin E, vitamin C, a glutathione precursor, an iron chelator, a copper chelator, copper, chromium, zinc and gold. |
| Current U.S. Class: | 424/702 |
| Patent References Cited: | WO 96/30007 October 1996 98/33495 August 1998 |
| Other References: | Abstract: Kirkley et al. Transfus Med 1998, 8(3), 195-204. cited by examiner Thomson Analyst 1998, 123, 827-831. cited by examiner Burke et al. Biological Trace Element Research 1992, 33, 151-3. cited by examiner T. Zimmermann et al., “Selensubstitution bei Sepsispatienten. Eine prospektiv randomisierte Studie.”, Medizinische Klinik, Sep. 15, 1997, 92 Suppl 3 P3-4. cited by other R. Gartner et al., “Selensubstitution bei Sepsispatienten” Medizinische Klinik, 92/Suppl. 3 (12-14). cited by other J. Borner et al., “Selensubstitution bei schweren entzunddichen chirurgischen Krankheitsbildern sowie Verbrennungen und Verbruhungen im Kindesalter.” Medizinische Klinik, Sep. 15, 1997, 92 Suppl 3 P17-9. cited by other Chemical Abstracts 108:149240 (Apr. 1988). cited by other Chemical Abstracts 127:171274 (Sep. 1997). cited by other Chemical Abstracts 129:134509 (Sep. 1998). cited by other Medline Abstract, accession No. 89032644 (1988). cited by other Chemical Abstracts, 116:150492 (1992). cited by other Hofbauer, L.C. et al., “Selenium-induced thyroid dysfunction,” Postgraduate Medical Journal, vol. 73(856), Feb. 1997, pp. 103-104. cited by other Medline Abstract, accession No. 89114296 (1989). cited by other |
| Primary Examiner: | Arnold, Ernst V |
| Attorney, Agent or Firm: | Young & Thompson |
| Accession Number: | edspgr.07635491 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|